Summary
The most recent Ebola virus outbreak in West Africa –
unprecedented in the number of cases and fatalities, geographic distribution,
and number of nations affected – highlights the need for safe,
effective, and readily available antiviral agents for treatment and prevention
of acute Ebola virus (EBOV) disease (EVD) or sequelae1. No antiviral therapeutics have yet
received regulatory approval or demonstrated clinical efficacy. Here we describe
the discovery of a novel anti-EBOV small molecule antiviral, GS-5734, a
monophosphoramidate prodrug of an adenosine analog. GS-5734 exhibits antiviral
activity against multiple variants of EBOV in cell-based assays. The
pharmacologically active nucleoside triphosphate (NTP) is efficiently formed in
multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as
an alternate substrate and RNA-chain terminator in primer-extension assays
utilizing a surrogate respiratory syncytial virus RNA polymerase. Intravenous
administration of GS-5734 to nonhuman primates resulted in persistent NTP levels
in peripheral blood mononuclear cells (half-life = 14 h) and
distribution to sanctuary sites for viral replication including testes, eye, and
brain. In a rhesus monkey model of EVD, once daily intravenous administration of
10 mg/kg GS-5734 for 12 days resulted in profound suppression of EBOV
replication and protected 100% of EBOV-infected animals against lethal
disease, ameliorating clinical disease signs and pathophysiological markers,
even when treatments were initiated three days after virus exposure when
systemic viral RNA was detected in two of six treated animals. These results
provide the first substantive, post-exposure protection by a small-molecule
antiviral compound against EBOV in nonhuman primates. The broad-spectrum
antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses
– including filoviruses, arenaviruses, and coronaviruses –
suggests the potential for expanded indications. GS-5734 is amenable to
large-scale manufacturing, and clinical studies investigating the drug safety
and pharmacokinetics are ongoing.
All classes of antiretroviral (ARV) therapy have been associated with asymptomatic elevations of alanine aminotransferase/aspartate aminotransferase (ALT/AST) levels, and much less frequently with serious, and at times life threatening, clinical liver hepatotoxicity. The relationship between the risk of developing serious clinical liver injury and the rate and severity of elevated asymptomatic ALT/AST levels is poorly understood. Boehringer Ingelheim has recently completed the Viramune Hepatic Safety Project; its primary objective was to identify risk factors for antiretroviral-associated hepatotoxicity. Data from 1731 nevirapine-treated patients and 1912 control patients who took part in Boehringer Ingelheim-controlled clinical trials as well as 814 nevirapine-treated patients in uncontrolled trials were analyzed. Risk factors for asymptomatic ALT/AST elevations during nevirapine therapy included baseline elevations of ALT/AST levels > 2.5x upper limit of normal (RR = 4.3, p < .01) and co-infection with hepatitis B (RR = 2.3, p < .01) or hepatitis C (RR = 5.2, p < .01). An analysis of ALT/AST elevations > 5x ULN for patients stratified by baseline CD4 cell count demonstrated that men with > or = 400 CD4 cells/mm3 were at increased risk of asymptomatic transaminase elevations while taking nevirapine (RR = 1.6, p < .01). No consistent CD4 cell count cutoff could be identified in women that was associated with an increased risk of ALT/AST elevations. Analyses from five large observational cohorts (N = 8711) demonstrated no significant differences in the rate of serious hepatic events among antiretroviral regimens, including between the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Use of nevirapine was not associated with a significantly increased risk of clinical hepatotoxic events, including liver failure or liver related death, compared to therapy with other antiretroviral drugs.
Because stimulation of CD4+ lymphocytes leads to activation of human immunodeficiency virus-type 1 (HIV-1) replication, viral spread, and cell death, adoptive CD4+ T cell therapy has not been possible. When antigen and CD28 receptors on cultured T cells were stimulated by monoclonal antibodies (mAbs) to CD3 and CD28 that had been immobilized, there was an increase in the number of polyclonal CD4+ T cells from HIV-infected donors. Activated cells predominantly secreted cytokines associated with T helper cell type 1 function. The HIV-1 viral load declined in the absence of antiretroviral agents. Moreover, CD28 stimulation of CD4+ T cells from uninfected donors rendered these cells highly resistant to HIV-1 infection. Immobilization of CD28 mAb was crucial to the development of HIV resistance, as cells stimulated with soluble CD28 mAb were highly susceptible to HIV infection. The CD28-mediated antiviral effect occurred early in the viral life cycle, before HIV-1 DNA integration. These data may facilitate immune reconstitution and gene therapy approaches in persons with HIV infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.